Evaluates multimeric LLP2A probes for improved tumor targeting in melanoma, suggesting effective theranostic applications.
integrin (VLA-4) has shown promise for molecular imaging, but its monomeric form exhibits rapid clearance and limited tumor retention, restricting its therapeutic potential. This study aimed to develop multimeric LLP2A probes with improved tumor uptake and retention. METHODS: Seven structurally distinct multimeric LLP2A derivatives were designed and synthesized, and their in vivo performance was compared with the monomeric analogue T4 in B16F10 melanoma mice using PET imaging, SPECT/CT imaging, biodistribution and therapy evaluation. RESULTS: Lu]Lu-LLP2A-Pol-1 significantly delayed tumor growth. CONCLUSION: A multimeric LLP2A probe with significantly enhanced tumor uptake and retention was successfully identified, providing a promising candidate for melanoma theranostics.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: